Sigma Life Science Obtains Global License for Kyoto University's iPS Cell Patent Portfolio

Sigma Life Science has acquired a worldwide license to use Kyoto University's induced pluripotent stem (iPS) cell patent portfolio.

Sigma-Aldrich Corporation announced Tuesday that Sigma Life Science, its innovative biological products and services research business, has acquired a worldwide license to use Kyoto University's induced pluripotent stem (iPS) cell patent portfolio.

Sigma Life Science, leveraging its zinc finger protein platform and stem cell technology portfolio, is now poised to develop a new set of differentiated tools for both the drug discovery and preclinical research communities. These tools will include novel iPS-cells, iPS-cell derived primary cells, novel assays, custom cell line development and ADME/Toxicology services. Under the terms of the agreement, iPS Academia Japan, Inc. (AJ) will receive a license fee from Sigma-Aldrich.

iPS cell technology can create pluripoten